We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Roche Introduces new X-tremeGENE DNA Transfection Reagents with High Efficiency Low Cytotoxicity
Product News

Roche Introduces new X-tremeGENE DNA Transfection Reagents with High Efficiency Low Cytotoxicity

Roche Introduces new X-tremeGENE DNA Transfection Reagents with High Efficiency Low Cytotoxicity
Product News

Roche Introduces new X-tremeGENE DNA Transfection Reagents with High Efficiency Low Cytotoxicity


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Roche Introduces new X-tremeGENE DNA Transfection Reagents with High Efficiency Low Cytotoxicity"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Roche has announced the introduction of two new high-performance DNA transfection reagents for its innovative cellular analysis portfolio for life science research.

Designed for commonly used and hard-to-transfect cell lines, the X-tremeGENE 9 and X-tremeGENE HP reagents offer high efficiency, reproducibility and cell survival rates, compared to leading transfection reagents, to deliver viable cells and help accelerate research efforts. Both reagents support a wide variety of cellular and molecular research applications, such as gene expression analysis and protein production.

The two new products build on Roche’s 20 years of experience with transfection reagents. The X-tremeGENE 9 reagent offers performance across a wide variety of commonly used cell lines while Roche’s X-tremeGENE HP reagent is especially well suited for cell lines that are difficult to transfect or not easily transfected with other reagents.

Both reagents combine low cytotoxicity with high efficiency and reproducibility, providing viable cells with more physiologically relevant results. They also offer easy-to-implement protocols: Researchers simply dilute the reagent, incubate it with plasmid DNA, and pipette it directly onto cells. The simple process enables researchers to spend less time optimizing the reagent and more time advancing their research.

Both reagents function well in the presence or absence of serum and remain stable after repeated vial openings, helping to save researchers time and effort.
Advertisement